Related Experiment Video
Updated: Oct 21, 2026

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson's disease
Wenwen Chen1,2,3, Yejing Zhang1,2, Xinrui Zhou4
1Department of Neurology, Affiliated Hospital of Nantong University, Nantong 226001, P.R. China.
Abstract:
Parkinson's disease (PD) is driven in part by neuroinflammation. We investigated whether the transcription factor BCL11B contributes to dopaminergic neurodegeneration in this context. Transcriptome sequencing of MPTP-induced PD mice revealed BCL11B upregulation, which was confirmed in MPP+-treated MN9D cells, MPTP-lesioned mice, and dopaminergic neurons exposed to inflammatory conditioned medium. BCL11B knockdown attenuated dopaminergic neuron loss, reduced apoptosis, improved motor deficits, and partially blocked JAK2/STAT3 pathway activation in both inflammatory and MPTP-induced PD models. Mechanistically, BCL11B mediated neurotoxicity through the JAK2/STAT3 pathway, with acetylation modifications potentially modulating its activity. These findings establish BCL11B as a key regulator of neuroinflammation and dopaminergic survival in PD, and suggest that targeting BCL11B may offer a therapeutic approach for this neurodegenerative disease.
Related Concept Videos
The JAK-STAT Signaling Pathway
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Parkinson Disease l: Introduction